EXPHARLAB LTD: public contracts won without a rival in Nigeria: 2 uncontested awards; 100% of its awards; 0 without a competition; 2 single bid.
Assay record ASY-NG-13B8EUK0AD · Cite as: Assay Systems, “EXPHARLAB LTD: public contracts won without a rival in Nigeria”, https://assay-systems.com/register/ng/uncontested/s/expharlab-ltd/
EXPHARLAB LTD won 2 of its 2 public contract awards in Nigeria without a rival from 2022-02-22 to 2023-02-02: 0 without a competition and 2 after a competition that drew a single bid. 1 buyer awarded it without a rival, the largest NATIONAL ORTHOPAEDIC HOSPITAL DALA KANO with 2.
An award is uncontested when the buyer had no rival offer to weigh: it was made without a competition (direct award, negotiated procedure without a call for tenders, sole-source or advance-notice contract), or a competition was held and only one bid arrived. Every count below is built award by award from the official notices. Awards to individuals are not included.
NATIONAL ORTHOPAEDIC HOSPITAL DALA KANO gave EXPHARLAB LTD 2 awards: 0 without a competition, 2 after a competition with a single bid. First 2022-02-22, latest 2023-02-02.
| Date | Buyer | How | Stated reason |
|---|---|---|---|
| 2023-02-02 | NATIONAL ORTHOPAEDIC HOSPITAL DALA KANO ocds-gyl66f-521027014-000402 | Single bid open | Request for quotation |
| 2022-02-22 | NATIONAL ORTHOPAEDIC HOSPITAL DALA KANO ocds-gyl66f-521027014-000257 | Single bid open | Direct Procurement |
Every uncontested award in Nigeria · All countries · EXPHARLAB LTD in the register
Source: contract awards published by the Bureau of Public Procurement of Nigeria (NOCOPO) and the Anambra and Osun State portals in the Open Contracting Data Standard (data.open-contracting.org), licensed under NOCOPO licence; awards from January 2016 to 30 September 2026, accessed 15 October 2026. Awards are matched to their buyer and supplier as published. Values in these notices often state a framework ceiling rather than a contract amount, so awards are counted, not summed. Updated 17 October 2026.